Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Vose, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vose, J. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 7:S13-S19, 1996
© 1996 European Society for Medical Oncology

Reviews

Classification and clinical course of low-grade non-Hodgkin's lymphomas with overview of therapy

J. M. Vose

Department of Internal Medicine, University of Nebraska Medical Center Omaha, NE, USA

Correspondence to: Julie M. Vose, MD Department of Internal Medicine University of Nebraska Medical Center 600 S. 42nd Street Box 98330 Omaha, NE 68198-3330 USA

Low-grade non-Hodgkin's lymphoma (NHL) presents a formidable treatment challenge to oncologists. This review evaluates the various methods of disease and patient management. The natural history of various subtypes of lowgrade NHL and the classification according to the National Cancer Institute Working Formulation are discussed in this review. Additionally, the various therapies in use; radiotherapy alone and combined with chemotherapy, chemotherapy with single alkylating agents such as chlorambucil and combination therapies, autologous and allogenic bone marrow transplantation, and therapy with purine analogs, such as chlorodeoxyadenosine and fludarabine. Patient survival in various studies using these treatment modalities are discussed. Treatment options need to be combined with the use of prognostic models, such as the International Index for optimal care of this difficult-to-treat group of patients.

bone marrow transplantation, chemotherapy, non-Hodgkin's lymphoma, purine analogs, radiotherapy


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.